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Abstract
Objective: Atherosclerosis is characterized by a chronic inflammatory response involving activated T cells and impairment
of natural killer (NK) cells. An increased T cell activity has been associated with plaque instability and risk of acute cardiac
events. Lymphocyte analyses in blood are widely used to evaluate the immune status. However, peripheral blood contains
only a minor proportion of lymphocytes. In this study, we hypothesized that thoracic lymph nodes from patients with stable
angina (SA) and acute coronary syndrome (ACS) might add information to peripheral blood analyses.
Methods: Peripheral blood and lymph nodes were collected during coronary by-pass surgery in 13 patients with SA and 13
patients with ACS. Lymphocyte subpopulations were assessed by flow cytometry using antibodies against CD3, CD4, CD8,
CD19, CD16/56, CD25, Foxp3, CD69, HLA-DR, IL-18 receptor (R) and CCR4.
Results: Lymph nodes revealed a lymphocyte subpopulation profile substantially differing from that in blood including a
higher proportion of B cells, lower proportions of CD8
+ T cells and NK cells and a 2-fold higher CD4/CD8 ratio. CD4
+CD69
+
cells as well as Foxp3
+ regulatory T cells were markedly enriched in lymph nodes (p,0.001) while T helper 1-like (CD4
+IL-
18R+) cells were more frequent in blood (p,0.001). The only significant differences between ACS and SA patients involved
NK cells that were reduced in the ACS group. However, despite being reduced, the NK cell fraction in ACS patients
contained a significantly higher proportion of IL-18R
+ cells compared with SA patients (p,0.05).
Conclusion: There were several differences in lymphocyte subpopulations between blood and lymph nodes. However, the
lymphocyte perturbations in peripheral blood of ACS patients compared with SA patients were not mirrored in lymph
nodes. The findings indicate that lymph node analyses in multivessel coronary artery disease may not reveal any major
changes in the immune response that are not detectable in blood.
Citation: Backteman K, Andersson C, Dahlin L-G, Ernerudh J, Jonasson L (2012) Lymphocyte Subpopulations in Lymph Nodes and Peripheral Blood: A
Comparison between Patients with Stable Angina and Acute Coronary Syndrome. PLoS ONE 7(3): e32691. doi:10.1371/journal.pone.0032691
Editor: R. Lee Mosley, University of Nebraska Medical Center, United States of America
Received October 7, 2011; Accepted January 29, 2012; Published March 1, 2012
Copyright:  2012 Backteman et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: The work was funded by the Swedish Heart-Lung Foundation (20090489, www.hjart-lungfonden.se) and the Swedish Research Council (2008-2282,
www.vr.se). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: karin.backteman@lio.se
Introduction
Atherosclerosis is characterized by a chronic inflammatory
response and the immunological activity in the atherosclerotic
plaque is considered an important determinant in the disease
process. The transition from a stable plaque to an unstable rupture-
prone plaque has been associated with an increased number of
intra-plaque T cells exhibiting early signs of activation [1,2]. There
is a dominant expression of T helper (Th)1 cytokines, such as
interferon (IFN)-gamma in advanced human carotid and femoral
lesions [3] and recently, IFN-gamma was found to be highly
produced by CD4
+ T cells within human coronary plaques [4].
Previous reports have also shown that the adaptive immune
response in peripheral blood differs when comparing chronic and
acute manifestations of coronary artery disease. Compared with
patients with stable angina (SA), patients with acute coronary
syndrome (ACS) exhibit increased numbers of circulating CD4
+ T
cells with phenotypical characteristics of Th1 as well as enhanced
expression of both early and late activation markers [5,6,7,8,
9,10,11]. Interestingly, Steppich and coworkers found that the
activation of peripheral T cells in ACS did not correlate with
markers of myocardial damage suggesting that T cell activation
might have been a plaque destabilizing factor preceding the acute
cardiac event [11]. However, a few studies have failed to
demonstrate elevations in T cell activation markers or serologic
evidence for increased IFN-gamma production in ACS compared
with SA [12,13]. Other studies have reported differences between
SA and ACS regarding other lymphocyte populations in
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regulatory T (Treg) cells in patients with ACS [6,14,15].
Moreover, a reduction of Treg cells in ACS has been found to
be consistent with an expansion of Th1 cells [6].
One relevant question is to what extent the lymphocyte changes
in peripheral blood reflect the immune response in atherosclerotic
lesions. Probably only 2% of the lymphocyte pool is present in the
peripheral blood [16]. Lymphocytes recirculate continuously
between the blood and lymphoid organs. In the lymph nodes,
where 40% of the total amount of lymphocytes is assumed to
reside, the adaptive immune response is both initiated and
regulated. The investigation of regional lymph nodes may thus
have the potential to provide new insight into the immune
activation of coronary artery disease. In the present study, we
examined the distribution of lymphocyte subpopulations in
thoracic lymph nodes from patients with SA and ACS hypothe-
sizing that lymph node analyses reveal changes in the immune
response that are not detectable in peripheral blood.
Methods
Ethics Statement
Written informed consent was obtained from study participants
and the study protocol was approved by the regional ethics
committee at Linko ¨ping University. The study was conducted in
accordance with ethical guidelines of Declaration of Helsinki.
Selection of subjects and collection of samples
We included 26 patients with multivessel coronary artery
disease that were referred for coronary artery bypass surgery
(CABG) at the Department of Thoracic Surgery, University
Hospital, Linko ¨ping during 2008–2010. Thirteen SA patients
underwent elective surgery due to effort angina class II or III
according to Canadian Cardiovascular Society Classification and
without any worsening of symptoms the latest 3 months. Thirteen
ACS patients underwent surgery soon after a non-ST elevation
myocardial infarction, i.e. within 14 (11–19) days. In combination
with the clinical presentation, the diagnosis of non-ST elevation
myocardial infarction was based on typical ECG-changes (ST-T
segment depression and/or T-wave inversion) and elevated
troponin levels [17]. Patients were excluded if they had severe
heart failure, renal or hepatic disease, neoplastic disease,
immunologic disorders or treatment with immunosuppressive
agents.
During harvesting of the internal mammary artery for
subsequent use as an arterial graft to a coronary vessel, the
attentive surgeon occasionally (in approximately 20% of cases)
encounters lymph nodes in the adjacent tissues of the arterial
pedicle. Such lymph nodes are normally overlooked or trimmed
away from the pedicle and then discarded. In the present study we
collected this surgical waste material prior to administration of
heparin and extracorporeal circulation, i.e. in the initial phase of
surgery. Samples of venous peripheral blood were drawn into
EDTA tubes. Blood and lymph nodes were transported immedi-
ately after collection to the laboratory for analysis.
We also collected blood from 26 controls (20 men, mean age 67
years, range 49–77 and 6 women, mean age 69 years, range 62–
76) randomly selected from the population register. They were all
clinically healthy without taking any medication and with normal
routine laboratory tests.
Cell populations
Lymphocyte subpopulations from peripheral blood and lymph
nodes were measured by 6- or 7-color combinations. Cells were
stained with the following monoclonal antibodies against surface
markers: CD3-FITC (clone SK7), HLA-DR-FITC (clone L234),
CD56-PE (clone NCAM16.2), CD3-PerCP (clone SK7), CD4-
PerCP (clone SK7), CD45-PerCP (clone 2D1), CD4-PE Cy7
(clone SK3), CD56-PE Cy7 (clone NCAM16.2), CD69-PE Cy7
(clone FN50), CCR4-PE Cy7 (clone 1G1), CD19-APC (clone
J25C1), CD25-APC (clone 2A3), CD56-APC (clone NCAM16.2),
CD8-APC H7 (clone SK1), CD3-APC H7 (cloneSK7), CD3-
Pacific Blue (clone UCHT1), all from BD Biosciences, San Jose ´,
CA, US. Anti-interleukin (IL)-18 receptor (R)a-PE (clone 70625)
was purchased from R&D systems, Minneapolis, MN, US, and
anti-Foxp3-PE (clone PCH101) from eBioscience, San Diego, CA,
US.
Lymph node preparation
A single-cell suspension was prepared from the lymph node
within 1 hour after extirpation. The unfixed lymph node was first
cut into 3–5 mm pieces and then disaggregated mechanically into
single-cells by rotating knifes in a Medimachine (DAKO,
Hamburg, Germany). The cells were resuspended in phosphate
buffered saline and then filtrated with a 50 mm Filcons filter. The
cell concentration was adjusted to 20610
6/mL.
Fifty mL of the EDTA blood or lymph node suspension were
added to appropriate amounts of each antibody and incubated for
15 minutes in the dark at room temperature. Thereafter,
erythrocytes were lysed with 450 mL FACS
TM Lysing Solution
(BD Biosciences) for 15 minutes at room temperature in darkness.
After erythrocyte lysis, cells were washed with phosphate-buffered
saline with 2% human serum albumin before flow cytometry
analysis.
For intracellular staining with Foxp3, 100 mL of the EDTA
blood or lymph node suspension were permabilized according to
the manufacturer’s instructions. In brief; cells were incubated with
appropriate amounts of HLA-DR, CD4, CD69, CD25 and CD3
and erythrocytes lysed. Fixation/permeabilization buffer
(eBioscience) was added and followed by incubation for 30 min
at 4uC in darkness. The antibody against Foxp3 was added
followed by incubation for 30 min at 4uC in darkness. Finally the
cells were washed, resuspended in washing buffer and immediately
analysed by flow cytometry.
Flow cytometry gating and analysis
The analyses of lymphocytes subpopulations were performed
on a FACSCanto II (BD Biosciences) equipped with 3 lasers, blue
488 nm, a red 633 nm and a violet 405 nm. Control of the
instrument settings was done daily with 7-color Setup Beads
TM
with FACSDiva
TM software or Cytometer Setup and Tracking
beads
TM (BD Biosciences) with Cytometer Setup and Track-
ing
TM software according to the standard procedure. A median of
23 500 (range 6,200–90,300) peripheral lymphocytes and 95 000
(range 4,800–116,700) lymph node cells were analysed. Data
analyses were performed with FACSDiva
TM 6.1.2 software (BD
Biosciences).
Lymphocytes were identified by CD45/forward scatter or side
scatter/forward scatter. Analysis of subpopulations was based on
contour gating. Gating strategies for the major lymphocyte
subpopulations in peripheral blood and lymph nodes are presented
in Figure 1. T reg cells were gated on the basis of CD3 expression
and CD4 expression that was slightly lower (dim) than the
remaining CD4 population, in combination with higher (bright)
expression of CD25 and Foxp3, as previously described [18] (see
Figure 2).
The flow cytometry laboratory gained accreditation status in
1996 according to ISO/IEC 17025 standards and we participate
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phenotyping (UK-Nequas and Equalis).
Statistical methods
Statistical analyses were done in SPSSH 17.0. Differences within
groups were analyzed using Wilcoxon signed-rank test while the
Mann-Whitney U test was used for between-group analyses.
Correlation analysis was performed using Spearman rank
correlation test. Statistical significances were set at a two-tailed
p-value of ,0.05. Values are given as medians and inter-quartile
range.
Results
Patients’ characteristics are listed in Table 1. All patients were
treated with low-dose aspirin and various combinations of nitrates,
beta-blockers and/or calcium antagonists. Ten of 13 SA patients
and 4 of 13 ACS patients were on long-term treatment, i.e. .2
months, with statin. The remaining 9 ACS patients had received
statin therapy after admission for the index event, i.e. within ,1
month. In addition, low-molecular weight heparin had been
introduced on admission and continued until the day before
surgery in all ACS patients. Four of 13 SA patients had a history of
prior myocardial infarction while one of 13 ACS patients had a
history of myocardial infarction before the index event.
The distributions of the major lymphocyte subpopulations in
peripheral blood compared with lymph nodes are presented in
Table 2. CD3
+ T cells constituted the majority of lymphocytes in
both blood and lymph nodes. In ACS patients, the proportion of
CD3
+ T cells was significantly higher in blood than in lymph
nodes and so was the proportion of CD8
+ T cells. In SA patients,
these differences showed the same pattern though less prominent
reaching significance only for CD8+ T cells. In contrast, the
proportions of CD4
+ T cells were similar in blood and lymph
nodes resulting in a CD4/CD8 ratio that was around 2-fold higher
in lymph nodes. B cells (CD3
2CD19
+) were abundantly present in
lymph nodes. NK cells (CD3
2CD56
+), on the other hand,
exhibited low numbers in lymph nodes compared with blood.
Among NK cells, the CD56
bright subset was more frequently found
in lymph nodes than in peripheral blood although the CD56
dim
Figure 1. Gating strategies for major lymphocyte populations. Gating strategies for major lymphocyte populations in peripheral blood and
lymph node respectively. Values are given as percent of lymphocytes. For CD56
bright subpopulation value is presented as percent of CD56. Examples
from one ACS (acute coronary syndrome) patient shows dot plots representative for both SA (stable angina) and ACS patients.
doi:10.1371/journal.pone.0032691.g001
Figure 2. Gating strategies for regulatory T cells. Different strategies for gating regulatory T cells in peripheral blood and lymph node
respectively. Panel A; Regulatory T cells is based on CD3 expression (not shown) ,slightly lower (dim) CD4 expression and high (bright) expression of
CD25, termed CD4
dim/CD25
bright [18] Panel B; Regulatory T cells based on CD3 expression (not shown), Foxp3 expression on CD4 population and with
limit of the CD8 population (=old gating strategy). Panel C; Regulatory T cells is based on CD3 expression (not shown), high (bright) expression of
CD25 (not shown), slightly lower (dim) CD4 expression and high Foxp3 expression. Values are given as percent CD3
+4
+. Examples from one ACS
(acute coronary syndrome) patient shows dot plots representative for both SA (stable angina) and ACS patients.
doi:10.1371/journal.pone.0032691.g002
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no significant differences in T cells, B cells, CD56
bright or CD56
dim
NK cell subsets between SA and ACS patients in either blood or
lymph nodes. However, in peripheral blood of ACS patients the
proportion of all NK cells (CD3
2CD56
+) was significantly reduced
compared with SA patients.
As shown in Table 3, the proportions of CD4
+ T cells
expressing the early activation marker CD69
+ were few in
peripheral blood but enriched in lymph nodes. The proportions
of CD4
+ and CD8
+ T cells expressing the late activation marker
HLA-DR were similar in blood and lymph nodes. No differences
were seen between SA and ACS patients regarding early or late
activation markers in either blood or lymph nodes (Figure S1).
The proportions of Treg cells are presented as either
CD4
dim25
bright, CD4
dim25
brightFoxp3
+ or CD4
+Foxp3
+ (Figure 2,
Table 3). Their proportions in peripheral blood were low and
around 2-fold increased in lymph nodes. There were no
differences in Treg distributions between SA and ACS patients.
The distribution of Foxp3 and CD69 in Treg cells
(CD4
dim25
bright) are shown in Figure 3. In lymph nodes, the
majority of Treg cells expressed both Foxp3 and CD69, 55 (42–69)
%, while in peripheral blood, only a minor fraction of Treg cells
expressed both Foxp3 and CD69, 3.7 (2.6–6.7) %. The coexpression
of Foxp3 and CD69 did not differ between SA and ACS patients.
The expression of IL-18R was used to identify the type 1 subsets
of CD4
+, CD8
+ and NK cells in peripheral blood and lymph
nodes [19,20] (Table 4) (Figure S2). Type 1 CD4
+ T cells appeared
to be more frequent in blood and type 1 CD8
+ T cells more
frequent in lymph nodes while the percentages of type 1 NK cells
were similar in blood and lymph nodes. However, certain
differences in type 1 cells were noted when comparing SA and
ACS patients. The differences between blood and lymph nodes
reached significance only for type 1 CD4
+ T cells in ACS patients
and for type 1 CD8
+ T cells in SA patients. The proportions of
type 1 NK cells in blood were significantly increased in ACS
patients compared with SA patients while no differences in type 1
NK cells was seen in lymph nodes.
The expression of CCR4 was used to identify type 2 CD4
+ T
cells. In peripheral blood, the proportions of CCR4
+CD4
+ T cells
were similar in SA and ACS patients, 14 (11–20) and 12 (9.0–19)
%, respectively. In lymph nodes, the CCR4
+CD4
+ T cells were
rare in both SA and ACS patients, 0.5 (0.2–0.7) and 0.5 (0.2–0.8)
%, respectively (Figure S2).
The proportions of major lymphocyte subpopulations in
peripheral blood did not show any significant correlations with
the proportions of their respective counterparts in lymph nodes,
except for CD8
+ (r=0.46, p,0.05). Among minor cell subpop-
Table 2. Distribution of major lymphocyte subpopulations.
SA patients (n=13) ACS patients (n=13) p
CD3
+ % of lymphocytes blood 67 (64–72) 72 (66–79) ns
lymph node 60 (48–67)1 55 (45–60)** ns
CD3
+4
+ % of lymphocytes blood 40 (27–51) 42 (35–46) ns
lymph node 43 (35–53) 41 (37–47) ns
CD3
+8
+ % of lymphocytes blood 24 (17–35) 29 (20–34) ns
lymph node 15 (9.3–21)* 14 (10–17)** ns
CD4/CD8 ratio blood 1.5 (1.0–3.2) 1.4 (1.2–1.9) ns
lymph node 2.8 (2.5–3.8)* 3.1 (2.7–4.0)** ns
CD3
219
+ % of lymphocytes blood 7.0 (5.6–11) 11 (6.9–13) ns
lymph node 39 (30–50)** 43 (38–53)** ns
CD3
256
+ % of lymphocytes blood 20 (12–23) 12 (9.4–19) ,0.05
lymph node 1.6 (1.2–2.0)** 1.5 (1.3–2.4)** ns
CD3
256
bright % of CD3256+ blood 4.6 (3.2–8.1) 6.5 (5.1–11) ns
lymph node 31 (21–55)** 34 (13–39)** ns
CD3
256
dim % of CD3256+ blood 96 (93–98) 94 (90–96) ns
lymph node 72 (48–82)** 69 (60–86)** ns
Values are given as median (inter-quartile range).
Significant differences between patients with stable angina (SA) and acute coronary syndrome (ACS) were found only in the CD3
256
+ population in blood, shown in the
column to the right.
Comparing blood and lymph nodes, there were significant differences in all populations except CD3
+4
+. Values * p,0.05, ** p,0.01 refer to differences between lymph
nodes and blood. Value 1 p=0.07 showed similar pattern for SA between lymph nodes and blood as for ACS.
doi:10.1371/journal.pone.0032691.t002
Table 1. Characteristics of SA and ACS patients.
SA
(n=13)
ACS
(n=13)
Age, years 74 (61–84) 66 (49–82)
Men (n) 10 10
Hypertension (n) 6 9
Diabetes (n) 2 6
Smokers, current (n) 0 1
Statin treatment (n)
long term 10 4
,1 month 3 9
Serum creatinine, mmol/L. 94 (78–141) 87 (64–117)
There were no significant differences in age or serum creatinine between SA
and ACS. Values are given as median (range).
doi:10.1371/journal.pone.0032691.t001
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+ and CD4
+Foxp3
+ T
cells in blood correlated weakly with their counterparts in lymph
nodes (r=0.48 and 0.40 respectively both p,0.05). In all subjects,
a positive correlation was seen between CD4
+CD69
+ T cells and
CD4
+Foxp3
+ T cells, r=0.62, p,0.001) in peripheral blood,
whereas no such correlation was seen in lymph nodes.
In order to confirm results in blood analyses, the percentages of
major lymphocyte subpopulations were determined in a group of
healthy controls (21 men, 6 women) in parallel with the patient
samples. The distributions of cells were as follows (median and i-q
range): CD3
+ 64 (58–72) %, CD3
+4
+ 39 (32–47) %, CD3
+8
+ 21
(18–28) %, CD3
+19
+ 9.6 (7.0–14) %, and CD3
216/56
+ (NK cells)
21 (13–31) %. Thus, all cell subpopulations in controls showed
values similar to patients except for NK cells that were significantly
more frequent in controls compared with ACS patients (p,0.05).
Discussion
In the present study, we describe the lymphocyte distribution in
thoracic lymph nodes of patients with multi-vessel coronary artery
disease making a direct comparison with the corresponding
populations in peripheral blood. The lymph nodes showed a cell
composition that was substantially different from blood lympho-
cytes with a higher proportion of B cells, lower proportions of
CD8
+ T cells and NK cells and a 2-fold higher CD4/CD8 ratio.
By ethical and practical reasons, the information on lymphocyte
composition in lymph nodes in healthy individuals is sparse.
However, our findings of lymphocyte distributions are in line with
previous reports comparing blood and lymph node samples mainly
obtained from patients with various types of cancer [21,22,
23,24,25]. Further, our findings of low expression of the early
activation marker CD69 in blood but substantially higher in
lymph nodes is also in agreement with a previous study
demonstrating the enrichment of CD69
+ lymphocytes in both
tumour reactive lymph nodes and control lymph nodes [25]. In
contrast, the finding of similar proportions of HLA-DR expressing
CD4
+ and CD8
+ T cells in blood and lymph nodes is not
corroborated by earlier studies showing higher proportions of
these cells in tumor lymph nodes than in blood [22,24], findings
Table 3. Distribution of T cell activation markers and regulatory T cells.
SA patients (=13) ACS patients (=13) p
CD3
+4
+69
+ % of CD3
+4
+ blood 1.2 (0.9–1.8) 1.0 (0.9–1.8) ns
lymph node 40 (38–50)** 49 (41–58)** ns
CD3
+4
+HLA/DR
+ % of CD3
+4
+ blood 14 (7.4–18) 10 (7.5–13) ns
lymph node 13 (10–17) 13 (9.9–16) ns
CD3
+8
+HLA/DR
+ % of CD3
+8
+ blood 37 (28–43) 32 (17–60) ns
lymph node 32 (25–49) 35 (22–54) ns
CD3
+4
dim25
bright % of CD3
+4
+ blood 2.9 (2.4–4.8) 3.0 (2.2–4.7) ns
lymph node 4.9 (3.7–6.6) 3.8 (2.0–8.0) ns
CD3
+4
dim 25
bright Foxp3
+ % of CD3
+4
+ blood 2.0 (1.5–3.0) 2.1 (1.3–2.8) ns
lymph node 4.5 (2.8–5.3)** 3.6 (2.1–6.3)** ns
CD3
+4
+ Foxp3
+ % of CD3
+4
+ blood 5.2 (3.1–5.6) 4.5 (3.0–5.1) ns
lymph node 15 (10–17)** 17 (11–19)** ns
Values are given as median (interquartile range).
No significant differences were noted between patients with stable angina (SA) and acute coronary syndrome (ACS). Comparing blood and lymph nodes, there were
significant differences in CD3
+4
+69
+ and T reg populations. Values ** p,0.01 refer to differences between lymph nodes and blood.
doi:10.1371/journal.pone.0032691.t003
Figure 3. Gating strategy for Foxp3 and CD69. Gating strategy for Foxp3 and CD69 distribution on regulatory T cells in peripheral blood and
lymph node respectively. The CD69/Foxp3 subset is based on CD4
dim/CD25
bright (Fig. 2A). Values are given as percent CD4
dim/CD25 bright. Examples
from one ACS (acute coronary syndrome) patient shows dot plots representative for both SA (stable angina) and ACS patients.
doi:10.1371/journal.pone.0032691.g003
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peripheral blood in the diagnosis of immune activation.
Lymphocyte analyses in blood are widely used to evaluate the
immune status in patients with various clinical presentations of
coronary artery disease. There are several reports of enhanced
systemic T cell activation, assessed by type 1 CD4
+ T cells and IFN-
gamma production, in ACS compared with SA patients
[5,6,7,8,9,10,11] whereas a few others have shown similar levels
ofsystemicTcellactivationinbothACSandSA[12,26].According
toRanjbaranandcoworkers[13],activation ofthe IFN-gammaaxis
was not associated with ACS but with a worse outcome at 1-year
follow-up in both ACS and SA patients. In our study, there were no
significant differences in CD4
+ T cells, CD8
+ T cells and activated
T cell subsets between SA and ACS patients in either blood or
lymph nodes. However, in ACS patients the proportions of IL-
18R
+CD4
+ T cells were significantly higher in blood than in lymph
nodes suggesting that an enhanced type 1 CD4
+ T cell response in
ACS patients may still exist in peripheral blood. The lack of major
differences in immune status between SA and ACS may have
several explanations. Since a median of 14 days passed between the
ACS and surgery, it may be argued that an initial Th1 activation in
ACS has declined when the myocardial injury is manifest. Another
plausible explanation for the lack of difference between ACS and
SA patients is that the T cell activation in ACS has become
attenuated by statin therapy. While a majority of the ACS patients
had received treatment less than 1 month it is known that Statin
treatment exerts rapid immunomodulatory effects in ACS patients
by inhibiting the Th1 response within a few days [27].
There is growing evidence that Treg cells exert atheroprotective
effects through suppressive actions on Th1 polarization. Two
previous studies have shown reduced numbers of circulating
Treg cells in ACS compared with SA [6,15]. However, in our
study the proportions of Treg cells, defined as CD4
dim25
bright or
CD4
dim25
brightFoxp3
+ T cells did not differ between SA and ACS
in either blood or lymph nodes. Foxp3 was not only expressed in
CD4
dim25
bright, i.e. strictly defined Treg cells [18], but also in
CD25
dim CD4
+ T cells, probably reflecting an activated T cell
fraction. A transient expression of Foxp3 in human CD25
2CD4
+
T cells has been shown after in vitro stimulation, although without
the gain of suppressive function [28]. Furthermore, we found that
CD4
+Foxp3
+ T cells in blood but not in lymph nodes were
strongly correlated with circulating CD4
+CD69
+ T cells support-
ing that they may represent a fraction of activated T cells in the
circulation.
The only difference in immune status between SA and ACS
involved NK cells that were significantly reduced in peripheral
blood, but not in lymph nodes, of ACS patients. As expected, the
CD56
dim NK cell fraction dominated over the CD56
bright NK cell
fraction, in blood and to a lesser extent in lymph nodes [29]. In a
previous study, we demonstrated that CD56
dim NK cells in blood
were reduced in both SA and ACS patients compared with healthy
individuals with the largest difference observed between ACS
patients and controls [14]. We also reported that NK cells in
patients were more prone to become activated and to undergo
apoptosis ex vivo thus speculating that this could result in declined
numbers of circulating NK cells [14,30]. The discrepant results of
NK cell proportions in SA patients and controls in our two studies
may be explained by different time points of blood sampling and
differences in clinical presentation; the present study comprising a
more homogenous group with optimal anti-anginous medication.
Nevertheless, the increased subfraction of circulating type 1 NK
cells (IL-18R
+) in ACS compared with SA indicates a more
activated state of NK cells in the ACS patients. In vitro, the
expression of IL-18R is associated with a dramatic increase in the
production of type 1 cytokines like IFN-gamma [31,32]. We have
also recently seen that the plasma levels of IL-15, a cytokine with a
distinct role in human NK cell activation [33], is increased in ACS
patients (n=20) compared with healthy controls (n=37), (3.1
(2.7–3.6) vs 2.5 (2.2–3.2) pg/ml, p,0.05, (L. Jonasson, unpub-
lished observations), a finding that may further support an
increased activation state of NK cells in ACS. Still, we cannot
exclude that the loss of circulating NK cells in ACS patients, due
to activation or not, is merely the result of myocardial necrosis.
Lymphocytes are continuously moving between different
compartments and a large amount of lymphocytes reside in
lymph nodes. Therefore, a ‘‘snapshot’’ analysis of blood
lymphocytes may not be representative of the current immune
status. To our knowledge, this is the first study that makes a direct
comparison between lymphocytes in lymph nodes and peripheral
blood of patients with SA and ACS. By obvious reasons, the access
to lymphoid tissue in patients with coronary artery disease was
very limited not allowing us to include a larger number of patients
or to collect more lymph nodes per patients. Based on the
literature, upper mediastinal lymph nodes receive drainage from
the heart whereas it is not clear from where internal mammary
artery lymph nodes, used in this study, collect blood [34]. Thus, it
is a potential limitation that the lymph nodes investigated may not
directly be connected to the heart, although there are several
connections across the highly dynamic lymph node network.
To summarize, we found several diversities in lymphocyte
composition between lymph nodes and peripheral blood. Howev-
er, the analysis of thoracic lymph nodes did not reveal any major
Table 4. Distribution of type 1 lymphocyte subsets.
SA patients (n=13) ACS patients (n=13) p
IL-18R
+ % of CD4
+ blood 4.9 (3.2–6.9) 6.3 (3.9–7.7) ns
lymph node 2.0 (1.5–4.6) 2.5 (1.8–4.8)* ns
IL-18R
+ % of CD8
+ blood 3.4 (2.5–4.9) 5.3 (2.8–7.5) ns
lymph node 6.5 (4.9–15)** 5.9 (4.1–25) ns
IL-18R
+ % of NK cells blood 3.4 (2.7–4.9) 7.3 (4.4–12) ,0.01
lymph node 3.7 (2.7–5.5) 5.6 (2.1–9.1) ns
Values are given as median (interquartile range).
Significant differences between patients with stable angina (SA) and acute coronary syndrome (ACS) were seen only in the IL
218R
+ % of NK cell population in blood.
Comparing blood and lymph nodes, there were significant differences in IL
218R
+ % of CD4
+ population for ACS and in IL
218R
+ % of CD8
+ population for SA. Values *
p,0.05, ** p,0.01 refer to differences between lymph nodes and blood.
doi:10.1371/journal.pone.0032691.t004
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PLoS ONE | www.plosone.org 7 March 2012 | Volume 7 | Issue 3 | e32691changes in immune status between SA and ACS patients. The few
significant changes observed in peripheral blood were not
mirrored in lymph nodes. Although our results, due to the sample
size, should be interpreted with caution, they indicate that lymph
node analyses in multivessel coronary artery disease may not
reveal any major changes in the immune response that are not
detectable in peripheral blood.
Supporting Information
Figure S1 Gating strategies for activation markers.
Gating strategies for activation markers in peripheral blood and
lymph node. T cells were defined by their CD3 expression (panel A)
andthentransferred forevaluationoftheCD4cells(panelB,CD69;
panel C, HLA-DR) and CD8 cells (panel D, HLA-DR). Values are
given as percent of CD4 and CD8, respectively. Examples from one
ACS (acute coronary syndrome) patient shows dot plots represen-
tative for both SA (stable angina) and ACS patients.
(TIFF)
Figure S2 Gating strategies for type 1 (IL-18 R
+) and
type 2 (CCR4
+). Gating strategies for type 1 (IL-18 R
+) and type
2 (CCR4
+) lymphocyte subsets in peripheral blood and lymph
node. T cells were defined by their CD3 expression (panel A) and
then transferred to panels B, C and E for evaluation of the CD4
and CD8 subsets, while CD56
+ NK cells (panel D) were defined by
their lack of CD3 expression in panel A. Values are given as
percent of CD4, CD8 and CD56, respectively. Examples from one
ACS (acute coronary syndrome) patient shows dot plots represen-
tative for both SA (stable angina) and ACS patients.
(TIF)
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